KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Equity (2018 - 2026)

Amneal Pharmaceuticals has reported Return on Equity over the past 8 years, most recently at 0.01% for Q4 2025.

  • For Q4 2025, Return on Equity fell 2.0% year-over-year to 0.01%; the TTM value through Dec 2025 reached 0.01%, down 2.0%, while the annual FY2025 figure was 0.01%, 3.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.01% at Amneal Pharmaceuticals, down from 0.01% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.06% in Q1 2024 and troughed at 0.02% in Q1 2023.
  • A 5-year average of 0.0% and a median of 0.0% in 2021 define the central range for Return on Equity.
  • Biggest five-year swings in Return on Equity: increased 7bps in 2024 and later decreased -6bps in 2025.
  • Year by year, Return on Equity stood at 0.0% in 2021, then crashed by -2605bps to 0.01% in 2022, then surged by 59bps to 0.01% in 2023, then surged by 230bps to 0.01% in 2024, then plummeted by -295bps to 0.01% in 2025.
  • Business Quant data shows Return on Equity for AMRX at 0.01% in Q4 2025, 0.01% in Q3 2025, and 0.0% in Q2 2025.